Skip to main content

Cancer

 

Clinical courses

 

Clinical courses

  • Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has entered a worldwide collaboration and license agreement with Tesaro, Inc., for exclusive rights to the investigational compound niraparib in prostate cancer. Niraparib is an orally administered poly polymerase (PARP) inhibitor, currently in late-stage development for patients with metastatic breast cancer and ovarian cancer.

  • Anti-oxidants are likely to be an effective method of treatment for elderly patients suffering from melanoma, finds a new study.It also identified that the older tumour cells in the worst form of skin cancer behave differently than the younger tumour cells.

  • Opening the door for new detection method that could allow doctors to diagnose patients with certain cancers far earlier than possible today, researchers have developed an optical sensor that they claim is one million times more sensitive than the current best available.

  • Researchers, including one of Indian-origin, have created a new molecule for prostate cancer that has shown great efficacy when tested in mice.The findings suggest that the new therapeutic might be a viable treatment for prostate cancer in humans too if it is found effective the future clinical trials.

  • A new technique developed by a team of chemists at Stanford University has shown promise to be thousands of times more sensitive than current techniques to diagnose diseases whether it is a cancer or a virus like HIV.

  • Russian researchers have developed a nanodrug that can identify a brain tumour during the first stage, and can subsequently be used for the diagnosis of other cancer types as well.

    (adsbygoogle = window.adsbygoogle || []).push({});
Subscribe to Cancer